Rui Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui Chen has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Bingshan Li
Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
7 shared publications - Qiang Wei
Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37235, USA
3 shared publications - Quan Wang
Vanderbilt University
3 shared publications - Chao Chen
MOE Key Laboratory of Rare Pediatric Diseases & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, and Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Chunyu Liu
MOE Key Laboratory of Rare Pediatric Diseases & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, and Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Qiang Wei
State Key Laboratory of Natural Medicines Department of Medicinal Chemistry School of Pharmacy China Pharmaceutical University Nanjing P. R. China
2 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Association for Computing Machinery (ACM)
- p. 11363-11374
scCotag: Prior-Informed Co-Optimal Transport for Robust Single-Cell Multi-Omics Integration
- 8 August 2026
- Published by Association for Computing Machinery (ACM)
- p. 11363-11374
Open AccessscCotag: Prior-Informed Co-Optimal Transport for Robust Single-Cell Multi-Omics Integration
- Open Access
- 29 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e08519
Analyses of GWAS and Sub‐Threshold Loci Lead to the Discovery of Dendrite Development and Morphology Dysfunction Underlying Schizophrenia Genetic Risk
Schizophrenia (SCZ) is highly polygenic, and its biological underpinnings remain unclear. In this study, a cost‐effective strategy of including sub‐threshold GWAS (subGWAS) loci (i.e., 5 × 10 −8 < P ≤ 10 −6 ) in analysis is explored to increase the inference power of novel pathways. A total of 180 subGWAS loci are identified from SCZ GWAS studies and are shown to contain substantial true genetic association signals. By jointly modeling GWAS (sigGWAS) and subGWAS loci, 304 high‐confidence risk genes (HRGs) are identified, as well as a novel category of biological processes detected only in subGWAS loci, i.e., dendrite development and morphogenesis (DDM). Two candidate DDM genes ( CUL7 and DCC ), whose risk alleles in GWAS are associated with increased expression, are examined, and it is observed that upregulation of these genes leads to reduced neurite length. It is further revealed that the DDM genes lead to disrupted regulatory programs of the transcription factors CUX1/2 and NEUROD1 . Collectively, the study identifies DDM as a novel biological process in SCZ susceptibility, with particular implications for DCC ‐ and CUL7 ‐mediated alterations in neurite development and reveals regulatory programs involved in perturbation of the two candidate genes.
- 29 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e08519
Open AccessAnalyses of GWAS and Sub‐Threshold Loci Lead to the Discovery of Dendrite Development and Morphology Dysfunction Underlying Schizophrenia Genetic Risk
Schizophrenia (SCZ) is highly polygenic, and its biological underpinnings remain unclear. In this study, a cost‐effective strategy of including sub‐threshold GWAS (subGWAS) loci (i.e., 5 × 10 −8 < P ≤ 10 −6 ) in analysis is explored to increase the inference power of novel pathways. A total of 180 subGWAS loci are identified from SCZ GWAS studies and are shown to contain substantial true genetic association signals. By jointly modeling GWAS (sigGWAS) and subGWAS loci, 304 high‐confidence risk genes (HRGs) are identified, as well as a novel category of biological processes detected only in subGWAS loci, i.e., dendrite development and morphogenesis (DDM). Two candidate DDM genes ( CUL7 and DCC ), whose risk alleles in GWAS are associated with increased expression, are examined, and it is observed that upregulation of these genes leads to reduced neurite length. It is further revealed that the DDM genes lead to disrupted regulatory programs of the transcription factors CUX1/2 and NEUROD1 . Collectively, the study identifies DDM as a novel biological process in SCZ susceptibility, with particular implications for DCC ‐ and CUL7 ‐mediated alterations in neurite development and reveals regulatory programs involved in perturbation of the two candidate genes.
- Open Access
- 30 June 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (6) , e1009814
Integration of multidimensional splicing data and GWAS summary statistics for risk gene discovery
A common strategy for the functional interpretation of genome-wide association study (GWAS) findings has been the integrative analysis of GWAS and expression data. Using this strategy, many association methods (e.g., PrediXcan and FUSION) have been successful in identifying trait-associated genes via mediating effects on RNA expression. However, these approaches often ignore the effects of splicing, which can carry as much disease risk as expression. Compared to expression data, one challenge to detect associations using splicing data is the large multiple testing burden due to multidimensional splicing events within genes. Here, we introduce a multidimensional splicing gene (MSG) approach, which consists of two stages: 1) we use sparse canonical correlation analysis (sCCA) to construct latent canonical vectors (CVs) by identifying sparse linear combinations of genetic variants and splicing events that are maximally correlated with each other; and 2) we test for the association between the genetically regulated splicing CVs and the trait of interest using GWAS summary statistics. Simulations show that MSG has proper type I error control and substantial power gains over existing multidimensional expression analysis methods (i.e., S-MultiXcan, UTMOST, and sCCA+ACAT) under diverse scenarios. When applied to the Genotype-Tissue Expression Project data and GWAS summary statistics of 14 complex human traits, MSG identified on average 83%, 115%, and 223% more significant genes than sCCA+ACAT, S-MultiXcan, and UTMOST, respectively. We highlight MSG’s applications to Alzheimer’s disease, low-density lipoprotein cholesterol, and schizophrenia, and found that the majority of MSG-identified genes would have been missed from expression-based analyses. Our results demonstrate that aggregating splicing data through MSG can improve power in identifying gene-trait associations and help better understand the genetic risk of complex traits.
- 30 June 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (6) , e1009814
Open AccessIntegration of multidimensional splicing data and GWAS summary statistics for risk gene discovery
A common strategy for the functional interpretation of genome-wide association study (GWAS) findings has been the integrative analysis of GWAS and expression data. Using this strategy, many association methods (e.g., PrediXcan and FUSION) have been successful in identifying trait-associated genes via mediating effects on RNA expression. However, these approaches often ignore the effects of splicing, which can carry as much disease risk as expression. Compared to expression data, one challenge to detect associations using splicing data is the large multiple testing burden due to multidimensional splicing events within genes. Here, we introduce a multidimensional splicing gene (MSG) approach, which consists of two stages: 1) we use sparse canonical correlation analysis (sCCA) to construct latent canonical vectors (CVs) by identifying sparse linear combinations of genetic variants and splicing events that are maximally correlated with each other; and 2) we test for the association between the genetically regulated splicing CVs and the trait of interest using GWAS summary statistics. Simulations show that MSG has proper type I error control and substantial power gains over existing multidimensional expression analysis methods (i.e., S-MultiXcan, UTMOST, and sCCA+ACAT) under diverse scenarios. When applied to the Genotype-Tissue Expression Project data and GWAS summary statistics of 14 complex human traits, MSG identified on average 83%, 115%, and 223% more significant genes than sCCA+ACAT, S-MultiXcan, and UTMOST, respectively. We highlight MSG’s applications to Alzheimer’s disease, low-density lipoprotein cholesterol, and schizophrenia, and found that the majority of MSG-identified genes would have been missed from expression-based analyses. Our results demonstrate that aggregating splicing data through MSG can improve power in identifying gene-trait associations and help better understand the genetic risk of complex traits.
- Open Access
Leveraging Gene-Level Prediction as Informative Covariate in Hypothesis Weighting Improves Power for Rare Variant Association Studies
Gene-based rare variant association studies (RVASs) have low power due to the infrequency of rare variants and the large multiple testing burden. To correct for multiple testing, traditional false discovery rate (FDR) procedures which depend solely on P-values are often used. Recently, Independent Hypothesis Weighting (IHW) was developed to improve the detection power while maintaining FDR control by leveraging prior information for each hypothesis. Here, we present a framework to increase power of gene-based RVASs by incorporating prior information using IHW. We first build supervised machine learning models to assign each gene a prediction score that measures its disease risk, using the input of multiple biological features, fed with high-confidence risk genes and local background genes selected near GWAS significant loci as the training set. Then we use the prediction scores as covariates to prioritize RVAS results via IHW. We demonstrate the effectiveness of this framework through applications to RVASs in schizophrenia and autism spectrum disorder. We found sizeable improvements in the number of significant associations compared to traditional FDR approaches, and independent evidence supporting the relevance of the genes identified by our framework but not traditional FDR, demonstrating the potential of our framework to improve power of gene-based RVASs.
Open AccessLeveraging Gene-Level Prediction as Informative Covariate in Hypothesis Weighting Improves Power for Rare Variant Association Studies
Gene-based rare variant association studies (RVASs) have low power due to the infrequency of rare variants and the large multiple testing burden. To correct for multiple testing, traditional false discovery rate (FDR) procedures which depend solely on P-values are often used. Recently, Independent Hypothesis Weighting (IHW) was developed to improve the detection power while maintaining FDR control by leveraging prior information for each hypothesis. Here, we present a framework to increase power of gene-based RVASs by incorporating prior information using IHW. We first build supervised machine learning models to assign each gene a prediction score that measures its disease risk, using the input of multiple biological features, fed with high-confidence risk genes and local background genes selected near GWAS significant loci as the training set. Then we use the prediction scores as covariates to prioritize RVAS results via IHW. We demonstrate the effectiveness of this framework through applications to RVASs in schizophrenia and autism spectrum disorder. We found sizeable improvements in the number of significant associations compared to traditional FDR approaches, and independent evidence supporting the relevance of the genes identified by our framework but not traditional FDR, demonstrating the potential of our framework to improve power of gene-based RVASs.
- Open Access
- 13 April 2020
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 16 (4) , e1007522
DRAMS: A tool to detect and re-align mixed-up samples for integrative studies of multi-omics data
Studies of complex disorders benefit from integrative analyses of multiple omics data. Yet, sample mix-ups frequently occur in multi-omics studies, weakening statistical power and risking false findings. Accurately aligning sample information, genotype, and corresponding omics data is critical for integrative analyses. We developed DRAMS (https://github.com/Yi-Jiang/DRAMS) to Detect and Re-Align Mixed-up Samples to address the sample mix-up problem. It uses a logistic regression model followed by a modified topological sorting algorithm to identify the potential true IDs based on data relationships of multi-omics. According to tests using simulated data, the more types of omics data used or the smaller the proportion of mix-ups, the better that DRAMS performs. Applying DRAMS to real data from the PsychENCODE BrainGVEX project, we detected and corrected 201 (12.5% of total data generated) mix-ups. Of the 21 mix-ups involving errors of racial identity, DRAMS re-assigned all data to the correct racial group in the 1000 Genomes project. In doing so, quantitative trait loci (QTL) (FDR<0.01) increased by an average of 1.62-fold. The use of DRAMS in multi-omics studies will strengthen statistical power of the study and improve quality of the results. Even though very limited studies have multi-omics data in place, we expect such data will increase quickly with the needs of DRAMS. Sample mix-up happens inevitably during sample collection, processing, and data management. It leads to reduced statistical power and sometimes false findings. It is of great importance to correct mixed-up samples before conducting any downstream analyses. We developed DRAMS to detect and re-align mixed-up samples in multi-omics studies. The basic idea of DRAMS is to align the data and labels for each sample leveraging the genetic information of multi-omics data. DRAMS corrects sample IDs following a two-step strategy. At first, it estimates pairwise genetic relatedness among all the data generated from all the individuals. Because the different data generated from the same individual should share the same genetics, we can group all the highly related data and consider that the data from one group have only one potential ID. Then, we used a “majority vote” strategy to infer the potential IDs for individuals in each group. Other information, such as matching of genetics-based and reported sexes, omics priorority, etc., were also used to identify the potential IDs. It has been proved that DRAMS performs very well in both simulation and PsychENCODE BrainGVEX multi-omics data.
- 13 April 2020
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 16 (4) , e1007522
Open AccessDRAMS: A tool to detect and re-align mixed-up samples for integrative studies of multi-omics data
Studies of complex disorders benefit from integrative analyses of multiple omics data. Yet, sample mix-ups frequently occur in multi-omics studies, weakening statistical power and risking false findings. Accurately aligning sample information, genotype, and corresponding omics data is critical for integrative analyses. We developed DRAMS (https://github.com/Yi-Jiang/DRAMS) to Detect and Re-Align Mixed-up Samples to address the sample mix-up problem. It uses a logistic regression model followed by a modified topological sorting algorithm to identify the potential true IDs based on data relationships of multi-omics. According to tests using simulated data, the more types of omics data used or the smaller the proportion of mix-ups, the better that DRAMS performs. Applying DRAMS to real data from the PsychENCODE BrainGVEX project, we detected and corrected 201 (12.5% of total data generated) mix-ups. Of the 21 mix-ups involving errors of racial identity, DRAMS re-assigned all data to the correct racial group in the 1000 Genomes project. In doing so, quantitative trait loci (QTL) (FDR<0.01) increased by an average of 1.62-fold. The use of DRAMS in multi-omics studies will strengthen statistical power of the study and improve quality of the results. Even though very limited studies have multi-omics data in place, we expect such data will increase quickly with the needs of DRAMS. Sample mix-up happens inevitably during sample collection, processing, and data management. It leads to reduced statistical power and sometimes false findings. It is of great importance to correct mixed-up samples before conducting any downstream analyses. We developed DRAMS to detect and re-align mixed-up samples in multi-omics studies. The basic idea of DRAMS is to align the data and labels for each sample leveraging the genetic information of multi-omics data. DRAMS corrects sample IDs following a two-step strategy. At first, it estimates pairwise genetic relatedness among all the data generated from all the individuals. Because the different data generated from the same individual should share the same genetics, we can group all the highly related data and consider that the data from one group have only one potential ID. Then, we used a “majority vote” strategy to infer the potential IDs for individuals in each group. Other information, such as matching of genetics-based and reported sexes, omics priorority, etc., were also used to identify the potential IDs. It has been proved that DRAMS performs very well in both simulation and PsychENCODE BrainGVEX multi-omics data.
- Open Access
DRAMS: A Tool to Detect and Re-Align Mixed-up Samples for Integrative Studies of Multi-omics Data
Studies of complex disorders benefit from integrative analyses of multiple omics data. Yet, sample mix-ups frequently occur in multi-omics studies, weakening statistical power and risking false findings. Accurately aligning sample information, genotype, and corresponding omics data is critical for integrative analyses. We developed DRAMS ( https://github.com/Yi-Jiang/DRAMS ) to Detect and Re-Align Mixed-up Samples to address the sample mix-up problem. It uses a logistic regression model followed by a modified topological sorting algorithm to identify the potential true IDs based on data relationships of multi-omics. According to tests using simulated data, the more types of omics data used or the smaller the proportion of mix-ups, the better that DRAMS performs. Applying DRAMS to real data from the PsychENCODE BrainGVEX project, we detected and corrected 201 (12.5% of total data generated) mix-ups. Of the 21 mix-ups involving errors of racial identity, DRAMS re-assigned all samples to the correct racial cluster in the 1000 Genomes project. In doing so, quantitative trait loci (QTL) (FDR<0.01) increased by an average of 1.62-fold. The use of DRAMS in multi-omics studies will strengthen statistical power of the study and improve quality of the results. Even though very limited studies have multi-omics data in place, we expect such data will increase quickly with the needs of DRAMS. Author summary: Sample mix-up happens inevitably during sample collection, processing, and data management. It leads to reduced statistical power and sometimes false findings. It is of great importance to correct mixed-up samples before conducting any downstream analyses. We developed DRAMS to detect and re-align mixed-up samples in multi-omics studies. The basic idea of DRAMS is to align the data and labels for each sample leveraging the genetic information of multi-omics data. DRAMS corrects sample IDs following a two-step strategy. At first, it estimates pairwise genetic relatedness among all the data generated from all the individuals. Because the different data generated from the same individual should share the same genetics, we can cluster all the highly related data and consider that the data from one cluster have only one potential ID. Then, we used a “majority vote” strategy to infer the potential ID for individuals in each cluster. Other information, such as match of genetics-based and reported sexes, omics priorority, etc., were also used to direct identifying the potential IDs. It has been proved that DRAMS performs very well in both simulation and PsychENCODE BrainGVEX multi-omics data.
Open AccessDRAMS: A Tool to Detect and Re-Align Mixed-up Samples for Integrative Studies of Multi-omics Data
Studies of complex disorders benefit from integrative analyses of multiple omics data. Yet, sample mix-ups frequently occur in multi-omics studies, weakening statistical power and risking false findings. Accurately aligning sample information, genotype, and corresponding omics data is critical for integrative analyses. We developed DRAMS ( https://github.com/Yi-Jiang/DRAMS ) to Detect and Re-Align Mixed-up Samples to address the sample mix-up problem. It uses a logistic regression model followed by a modified topological sorting algorithm to identify the potential true IDs based on data relationships of multi-omics. According to tests using simulated data, the more types of omics data used or the smaller the proportion of mix-ups, the better that DRAMS performs. Applying DRAMS to real data from the PsychENCODE BrainGVEX project, we detected and corrected 201 (12.5% of total data generated) mix-ups. Of the 21 mix-ups involving errors of racial identity, DRAMS re-assigned all samples to the correct racial cluster in the 1000 Genomes project. In doing so, quantitative trait loci (QTL) (FDR<0.01) increased by an average of 1.62-fold. The use of DRAMS in multi-omics studies will strengthen statistical power of the study and improve quality of the results. Even though very limited studies have multi-omics data in place, we expect such data will increase quickly with the needs of DRAMS. Author summary: Sample mix-up happens inevitably during sample collection, processing, and data management. It leads to reduced statistical power and sometimes false findings. It is of great importance to correct mixed-up samples before conducting any downstream analyses. We developed DRAMS to detect and re-align mixed-up samples in multi-omics studies. The basic idea of DRAMS is to align the data and labels for each sample leveraging the genetic information of multi-omics data. DRAMS corrects sample IDs following a two-step strategy. At first, it estimates pairwise genetic relatedness among all the data generated from all the individuals. Because the different data generated from the same individual should share the same genetics, we can cluster all the highly related data and consider that the data from one cluster have only one potential ID. Then, we used a “majority vote” strategy to infer the potential ID for individuals in each cluster. Other information, such as match of genetics-based and reported sexes, omics priorority, etc., were also used to direct identifying the potential IDs. It has been proved that DRAMS performs very well in both simulation and PsychENCODE BrainGVEX multi-omics data.
- 20 November 2017
- Published by Oxford University Press (OUP) in Plant Physiology
- Vol. 176 (1) , 819-835
Transcription Factor OsTGA10 Is a Target of the MADS Protein OsMADS8 and Is Required for Tapetum Development
This study aimed at elucidating regulatory components behind floral organ identity determination and tissue development. It remains unclear how organ identity proteins facilitate development of organ primordia into tissues with a determined identity, even though it has long been accepted that floral organ identity is genetically determined by interaction of identity genes according to the ABC model. Using the chromatin immunoprecipitation sequencing technique, we identified OsTGA10, encoding a bZIP transcription factor, as a target of the MADS box protein OsMADS8, which is annotated as an E-class organ identity protein. We characterized the function of OsTGA10 using genetic and molecular analyses. OsTGA10 was preferentially expressed during stamen development, and mutation of OsTGA10 resulted in male sterility. OsTGA10 was required for tapetum development and functioned by interacting with known tapetum genes. In addition, in ostga10 stamens, the hallmark cell wall thickening of the endothecium was defective. Our findings suggest that OsTGA10 plays a mediator role between organ identity determination and tapetum development in rice stamen development, between tapetum development and microspore development, and between various regulatory components required for tapetum development. Furthermore, the defective endothecium in ostga10 implies that cell wall thickening of endothecium is dependent on tapetum development.
- 20 November 2017
- Published by Oxford University Press (OUP) in Plant Physiology
- Vol. 176 (1) , 819-835
Transcription Factor OsTGA10 Is a Target of the MADS Protein OsMADS8 and Is Required for Tapetum Development
This study aimed at elucidating regulatory components behind floral organ identity determination and tissue development. It remains unclear how organ identity proteins facilitate development of organ primordia into tissues with a determined identity, even though it has long been accepted that floral organ identity is genetically determined by interaction of identity genes according to the ABC model. Using the chromatin immunoprecipitation sequencing technique, we identified OsTGA10, encoding a bZIP transcription factor, as a target of the MADS box protein OsMADS8, which is annotated as an E-class organ identity protein. We characterized the function of OsTGA10 using genetic and molecular analyses. OsTGA10 was preferentially expressed during stamen development, and mutation of OsTGA10 resulted in male sterility. OsTGA10 was required for tapetum development and functioned by interacting with known tapetum genes. In addition, in ostga10 stamens, the hallmark cell wall thickening of the endothecium was defective. Our findings suggest that OsTGA10 plays a mediator role between organ identity determination and tapetum development in rice stamen development, between tapetum development and microspore development, and between various regulatory components required for tapetum development. Furthermore, the defective endothecium in ostga10 implies that cell wall thickening of endothecium is dependent on tapetum development.
- Open Access
- 21 March 2017
- Published by Springer Nature in Molecular Autism
- Vol. 8 (1) , 1-12
Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism
Autism spectrum disorder (ASD) is one of the most highly heritable neuropsychiatric disorders, but underlying molecular mechanisms are still unresolved due to extreme locus heterogeneity. Leveraging meaningful endophenotypes or biomarkers may be an effective strategy to reduce heterogeneity to identify novel ASD genes. Numerous lines of evidence suggest a link between hyperserotonemia, i.e., elevated serotonin (5-hydroxytryptamine or 5-HT) in whole blood, and ASD. However, the genetic determinants of blood 5-HT level and their relationship to ASD are largely unknown. In this study, pursuing the hypothesis that de novo variants (DNVs) and rare risk alleles acting in a recessive mode may play an important role in predisposition of hyperserotonemia in people with ASD, we carried out whole exome sequencing (WES) in 116 ASD parent-proband trios with most (107) probands having 5-HT measurements. Combined with published ASD DNVs, we identified USP15 as having recurrent de novo loss of function mutations and discovered evidence supporting two other known genes with recurrent DNVs (FOXP1 and KDM5B). Genes harboring functional DNVs significantly overlap with functional/disease gene sets known to be involved in ASD etiology, including FMRP targets and synaptic formation and transcriptional regulation genes. We grouped the probands into High-5HT and Normal-5HT groups based on normalized serotonin levels, and used network-based gene set enrichment analysis (NGSEA) to identify novel hyperserotonemia-related ASD genes based on LoF and missense DNVs. We found enrichment in the High-5HT group for a gene network module (DAWN-1) previously implicated in ASD, and this points to the TGF-β pathway and cell junction processes. Through analysis of rare recessively acting variants (RAVs), we also found that rare compound heterozygotes (CHs) in the High-5HT group were enriched for loci in an ASD-associated gene set. Finally, we carried out rare variant group-wise transmission disequilibrium tests (gTDT) and observed significant association of rare variants in genes encoding a subset of the serotonin pathway with ASD. Our study identified USP15 as a novel gene implicated in ASD based on recurrent DNVs. It also demonstrates the potential value of 5-HT as an effective endophenotype for gene discovery in ASD, and the effectiveness of this strategy needs to be further explored in studies of larger sample sizes.
- 21 March 2017
- Published by Springer Nature in Molecular Autism
- Vol. 8 (1) , 1-12
Open AccessLeveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism
Autism spectrum disorder (ASD) is one of the most highly heritable neuropsychiatric disorders, but underlying molecular mechanisms are still unresolved due to extreme locus heterogeneity. Leveraging meaningful endophenotypes or biomarkers may be an effective strategy to reduce heterogeneity to identify novel ASD genes. Numerous lines of evidence suggest a link between hyperserotonemia, i.e., elevated serotonin (5-hydroxytryptamine or 5-HT) in whole blood, and ASD. However, the genetic determinants of blood 5-HT level and their relationship to ASD are largely unknown. In this study, pursuing the hypothesis that de novo variants (DNVs) and rare risk alleles acting in a recessive mode may play an important role in predisposition of hyperserotonemia in people with ASD, we carried out whole exome sequencing (WES) in 116 ASD parent-proband trios with most (107) probands having 5-HT measurements. Combined with published ASD DNVs, we identified USP15 as having recurrent de novo loss of function mutations and discovered evidence supporting two other known genes with recurrent DNVs (FOXP1 and KDM5B). Genes harboring functional DNVs significantly overlap with functional/disease gene sets known to be involved in ASD etiology, including FMRP targets and synaptic formation and transcriptional regulation genes. We grouped the probands into High-5HT and Normal-5HT groups based on normalized serotonin levels, and used network-based gene set enrichment analysis (NGSEA) to identify novel hyperserotonemia-related ASD genes based on LoF and missense DNVs. We found enrichment in the High-5HT group for a gene network module (DAWN-1) previously implicated in ASD, and this points to the TGF-β pathway and cell junction processes. Through analysis of rare recessively acting variants (RAVs), we also found that rare compound heterozygotes (CHs) in the High-5HT group were enriched for loci in an ASD-associated gene set. Finally, we carried out rare variant group-wise transmission disequilibrium tests (gTDT) and observed significant association of rare variants in genes encoding a subset of the serotonin pathway with ASD. Our study identified USP15 as a novel gene implicated in ASD based on recurrent DNVs. It also demonstrates the potential value of 5-HT as an effective endophenotype for gene discovery in ASD, and the effectiveness of this strategy needs to be further explored in studies of larger sample sizes.
- 16 September 2013
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Eco-Agriculture
- Vol. 21 (12) , 1500-1506
Composition and diversity of weed community in transgenic CryIAb rice field
- 16 September 2013
- Published by China Science Publishing & Media Ltd. in Chinese Journal of Eco-Agriculture
- Vol. 21 (12) , 1500-1506
Composition and diversity of weed community in transgenic CryIAb rice field